Page 20 - Labatt Brain Tumour Research Centre Annual Report 2023 to 2024

YEAR IN REVIEWYear in Review – Currently Held Grants
Dr. Vijay Ramaswamy
Molecular and functional characterization of
childhood ependymoma. Canadian Institutes of
Health Research
Phase I/lb trial of combined 5’azacitidine and
carboplatin for recurrent/refractory pediatric
brain and solid tumors and recurrent or refractory
ependymoma. Ontario Institute for Cancer
Research
Unravelling the DNA damage response.
SickKids Foundation
Targeting mTORC1 in high-risk medulloblastoma.
Meagan’s HUG (Meagan Bebenek Foundation)
Genomic determinants of outcome in high-risk
medulloblastoma of infancy. b.r.a.i.n.child
Dr. Jane McGlade
Identification of TBR1 protein interaction networks
in Group 4 medulloblastoma. Meagan’s HUG
(Meagan Bebenek Foundation)
Approaches to regulate CBL ubiquitin ligase
activity and control oncogenic tyrosine kinase
signaling. Canadian Institutes of Health Research
Alternative splicing and Numb protein isoform
function in cancer metastasis. Canadian Institutes
of Health Research
Targeting cancer splicing programs to prevent
metastatic progression. Canadian Cancer Society
Ubiquitin system regulation of epithelial polarity.
Natural Sciences and Engineering Research
Council of Canada
Dr. James Rutka
Establishment of a drug discovery and delivery
platform for diffuse intrinsic pontine glioma
(DIPG). Canadian Institutes of Health Research
Activity of GPX4 and GCH1 regulate sensitivity to
ferroptosis in medulloblastoma leptomeningeal
metastasis. b.r.a.i.n.child
The Brain Tumour Biobank at the Labatt Brain
Tumour Research Centre. Meagan’s HUG
(Meagan Bebenek Foundation)
Dr. Uri Tabori
Towards LNP vaccine immune-interception for
childhood cancer predisposition syndromes.
Alex’s Lemonade Stand Foundation
Upfront adaptive immunotherapy approach for
hypermutant glioblastoma in children, adolescents
and young adults. Canadian Institutes of Health
Research
Uncovering the mechanism and impact of novel
genetic and epigenetic promoter alterations on
tissue-specific mismatch repair deficient cancers.
Canadian Institutes of Health Research
Empowering next-generation researchers In
perinatal and child health (ENRICH). Canadian
Institutes of Health Research
Determining the cellular mechanisms of initiation
and evolution of hypermutant glioma. Canadian
Institutes of Health Research
Towards a preventive cancer vaccine for children
with constitutional mismatch repair deficiency.
The National Institutes of Health Research USA
U-R-Immune glioma: A pilot study investigating
upfront adaptive immunotherapy approach in
children, adolescent and young adult patients with
replication-repair deficient high-grade gliomas.
The Anticancer Fund
LOGIC: Development of a complementary diagnostic
for RRD detection. Genome Canada Grant
Dissecting the origins and microenvironment of
replication repair deficient hypermutant gliomas
for novel immune based therapies. Canadian
Institutes of Health Research
20
IMAGINE 2023-24